buy Amazon shares<\/a> or are interested in any other company, but the ultimate decision is strictly yours to make. We cannot give you personalized investment advice or make the investment decision for you.<\/p>\nStrong profitability and cash flows<\/h3>\n Despite slightly shrinking revenues in 2019 ($52 billion vs. nearly $54 billion in 2018), Pfizer\u2019s profit margins stood in excess of 30%, significantly up from 2018.<\/p>\n
While sales and profits can vary significantly in a business where old drugs lose their patents while new ones come to market, strong cash flows are key to continue growing and to reward shareholders. With over $12.5 billion in cash from operating activities, Pfizer has ample ability to invest in its R&D pipeline and pursue lucrative M&A deals.<\/p>\n
The spinoff of its Upjohn and Consumer Health businesses will shrink Pfizer\u2019s size significantly. Nevertheless, it will keep large stakes in the new businesses that will continue to contribute to its bottom line.<\/p>\n
Large drug pipeline and a history of innovation<\/h3>\n Pfizer is one of the most prolific pharmaceutical companies in terms of number of new drugs coming to market every year. At the end of 2019, it had 95 products in the pipeline, and marketed or distributed over 300 products in the US and worldwide.
Pfizer\u2019s 171-years long history of innovation in all domains, from disease-specific drugs to antibiotics, vaccines and over-the-counter remedies is remarkable.<\/p>\n
Refocusing of the group on the core business<\/h3>\n Pfizer\u2019s spinoff of its Upjohn division gives its shareholders a controlling stake in a new world leader in generic manufacturers. The merger of Upjohn with Mylan, one of the largest generic drug manufacturers in the world. Consequently, buying Pfizer shares before the merger will entitle the holder to a double dividend: one from Pfizer and one from Upjohn-Mylan.<\/p>\n
Similarly, the decision to merger Pfizer\u2019s and GSK\u2019s consumer healthcare businesses will create a world leader in many over-the-counter remedies and supplements.<\/p>\n
Consequently, the \u201cnew Pfizer\u201d will be able to focus on its core business of Biopharmaceuticals while receiving dividends and participating in the growth of two category leaders in generics and consumer healthcare.<\/p>\n
A strong position in the race for a coronavirus vaccine<\/h3>\n Since the beginning of the coronavirus crisis, Pfizer has partnered with NASDAQ-listed biotech firm BioNTech to develop a Covid-19 vaccine using novel mRNA technology. At the time of writing, the Pfizer-BioNTech partnership was among the front-runners in the race to develop the vaccine, with human testing beginning in Germany in April and a US study in May.<\/p>\n
In April, both firms announced their plan to produce millions of vaccine doses by the end of 2020, and hundreds of millions by the end of 2021. Pfizer is rumored to be ready to enter Phase III studies as early as July.<\/p>\n
Large and growing dividend paired with strong share buybacks<\/h3>\n In 2019, Pfizer paid $8 billion in dividends to shareholders and spend another ~$9 billion in share buybacks, bringing shareholder remuneration at almost $17 billion. Pfizer\u2019s generous and steadily growing dividend gives Pfizer shares a strong income component, even though the company may slow down its share repurchase program for optics.<\/p>\n
At the time of writing, the dividend yield on Pfizer shares was over 4.5%, an attractive proposition for investors looking for yield. In addition to the growth potential of the company, from vaccines and new drugs to participation in new generics and consumer healthcare giants.<\/p>\n
About Pfizer Shares<\/h2>\nCompany History & Business Model<\/h3>\n Pfizer is one of the world\u2019s largest pharmaceutical companies, with 2019 revenues approaching $52 billion and over 88,000 employees worldwide. Its products are sold in 125 countries. In 2018, eight of Pfizer\u2019s drugs generated over $1 billion in global sales.<\/p>\n
Founded in 1849, Pfizer is headquartered in New York City and is listed on the New York Stock Exchange. Pfizer shares are a component both of the Dow Jones Industrial Average and the S&P 500 indices. Pfizer\u2019s business is split into 3 divisions: Biopharmaceuticals, Upjohn (soon to merge with Mylan) and Consumer Healthcare. In 2019, 46% of its revenues came from the US, 9% from China, 8% from Japan and 37% from the rest of the world (with no market >8% of global sales).<\/p>\n
Biopharma is Pfizer\u2019s largest division, with just under $40 billion in 2019 revenues (up by almost $2 billion, or 5%, year-on-year). Pfizer develops and sells drugs in 6 key therapeutic areas: internal medicine, oncology, hospital, vaccines, inflammation & immunology and rare diseases, and had 6 products with 2019 sales exceeding $1 billion.<\/p>\n
Upjohn, Pfizer\u2019s second-largest division with $10 billion in 2019 revenues, is set to be merged with generic drug-maker Mylan in 2020. Pfizer will spin off Upjohn and merge it into Mylan via a tax-light structure called a Reverse Morris Trust, thus giving Pfizer shareholders 57% of the combined entity. With over $20 billion in revenues, the new company would become the uncontested global leader in generic drugs, giving it a strong advantage in a brutally competitive market.<\/p>\n
Last, Consumer Healthcare represented $2 billion in revenues in 2019. In July 2019, Pfizer announced the completion of a merger between its Consumer Healthcare division and UK-based pharma giant GlaxoSmithKline\u2019s consumer business. The new entity, owned 32% by Pfizer, is a world leader in overt-the-counter (i.e. prespriction-free) pain relief, respiratory medicines, oral health products vitamins, minerals and supplements.<\/p>\n
As a leader in branded and patented drugs, Pfizer faces several challenges including patent cliffs (large drop in sales when patents expire), threats from generics and FDA approvals that can prove exceedingly lengthy. Yet, in 2019, Pfizer had 95 products in its R&D pipeline, including 26 in Phase I, 37 in Phase II, 23 in Phase III and 9 products in the registration phase.<\/p>\n
Pfizer Share Price<\/h3>\n Pfizer is listed on the New York Stock Exchange under the NYSE:PFE ticker, and is a component of the Dow Jones Industrial Average and the S&P 500.<\/p>\n
Since January 2020, prior to the coronavirus crisis, Pfizer shares have lost a little over 17%, primarily due to the loss of exclusivity of its billion-dollar epilepsy and nerve pain Lyrica and the spinoff-plus-merger of the Upjohn division into Mylan.<\/p>\n
With a 95-drugs strong pipeline, including 32 products in Phase III and registration phase.<\/p>\n
Further, a merger between Upjohn and Mylan will create a world leader in generics, better position to compete in the market than Upjohn or Mylan alone.\u00a0 Similarly, the merger of its Consumer Healthcare business with that of GSK allows Pfizer to focus on its core Biopharma segment while retaining a large stake in a new consumer healthcare world leader.<\/p>\n
At the time of writing, the analyst consensus on Pfizer shares was between \u201cBuy\u201d and \u201cHold\u201d, with price targets for the next 12 months ranging from $35\u2013$53 (average of $40.3).<\/p>\n
How To Buy Pfizer Shares<\/h2>\n Now that we\u2019ve provided you with some background information on Pfizer shares, you may to want to invest in stocks<\/a> for yourself. If you do want to buy Pfizer shares, you can use this step-by-step walkthrough to learn how to invest in Pfizer.<\/p>\nIf you choose to use a different platform, the process remains largely the same.<\/p>\n
Step 1: Search for Pfizer (PFE) shares<\/h3>\n On the stock trading platform, use the search function to look up Pfizer or its ticker (PFE). You will see two kinds of search results: markets and people. The first one concerns tradable instruments such as shares or commodities. The second allows you to find other users, see their profiles and portfolio as well as their P&L statistics.<\/p>\n
Step 2: Select \u201cTrade\u201d to get started<\/h3>\n After doing your research carefully, including reading annual reports, press coverage and analyst commentaries, you are ready to buy Pfizer shares! Before clicking \u201cTrade\u201d, make sure you are using your own portfolio. If you simply wish to try your hand at trading, you can also use free demo account for free paper trading.<\/p>\n
When you are ready, click \u201cTrade\u201d to open the trading window and specify the direction, amount and options of your order.<\/p>\n
Step 3: Buy Pfizer Shares<\/h3>\n Once you\u2019re in the trading window, the first step is to specify whether to sell (including short-selling) or buy Pfizer shares. Long (\u201cbuy\u201d) orders with no leverage are executed directly while leveraged and short orders are made via CFDs.<\/p>\n
Next, specify how much you want to trade. You can set a specific number of shares (including fractions of shares) or a dollar amount to buy or sell. You will see the number of units and the exposure (in percentage and dollar amount) that the trade involves.<\/p>\n
The default order type is a market order, but you can specify limits and use special trade features such as leverage, stop-loss and take-profit,<\/p>\n
Last, review the fees at the bottom if your trade is via CFDs (no commissions on trades otherwise) and click \u201cOpen Trade\u201d or \u201cSet Order\u201d outside of market hours to complete your trade!<\/p>\n
Conclusion<\/h2>\n As mentioned many times in this article, Pfizer is one of the largest pharmaceutical companies in the world. With a renewed focus on biopharmaceuticals, strong margins and a healthy dividend, Pfizer shares are an attractive buy proposition.<\/p>\n
We strongly recommend that you read Pfizer\u2019s annual reports, press coverage and analyst commentaries to understand the company\u2019s business and key risks. This is particularly important in the pharmaceutical sector, where the risks and business dynamics are not always easy to grasp at first glance.<\/p>\n
FAQs<\/h2>\n <\/time><\/time>